A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog Alfa
← catalyst calendarSponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →. With Syneos Health.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
93actual
Sites
30
Countries
Austria, Croatia, Czechia +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-31 | actual | When the study began enrolling |
| Primary completion | 2026-06-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-02 | actual | The whole study's end, after follow-up |
| First posted | 2023-04-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hemophilia A, Severe
Intervention
- Drug: Efanesoctocog alfa — also filed as BIVV001
Primary outcome
what the primary-completion date above is the date OFChange from baseline in International Physical Activity Questionnaire (IPAQ) scoring
measured Baseline and month 24
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed